Published on

Toxicology – Trimethobenzamide


Description

Trimethobenzamide, marketed as Tigan, is an antiemetic medication.


Forms and Uses

Trimethobenzamide is used for the treatment of nausea and vomiting.

The usual adult dosage is approximately:

250 mg orally three times daily

or

200 mg intramuscularly or rectally every 6–8 hours.


Toxic Dose

The toxic dose is not well established.

Significant toxicity generally requires ingestion of a large amount of trimethobenzamide.


Pathophysiology

Trimethobenzamide is a nonphenothiazine antiemetic that acts primarily by depressing the chemoreceptor trigger zone.

In overdose, toxicity is mainly related to anticholinergic effects.

Some patients may also demonstrate effects consistent with α-adrenergic blockade, including abnormalities in pupillary size.


Epidemiology

Trimethobenzamide poisoning is uncommon.

When overdose occurs, toxicity is usually mild.


Causes

Significant poisoning is often associated with intentional overdose.

In very young children, inappropriate exposure may raise concern for neglect or abuse.

In older children and adolescents, intentional self-poisoning should be considered when clinically appropriate.


Pregnancy and Lactation

The historical FDA classification listed trimethobenzamide as Pregnancy Category C.

Animal studies demonstrated possible teratogenic or embryotoxic effects, while adequate controlled human studies were unavailable.


Differential Diagnosis

Other causes of an anticholinergic toxidrome include:

Atropine

Scopolamine

and

Antihistamines.


Clinical Features

Acute overdose predominantly produces anticholinergic manifestations, although CNS depression and cardiovascular abnormalities may also occur.


Vital Signs

Possible abnormalities include:

Tachycardia

Hyperthermia

Hypertension

or

Hypotension.


HEENT

Dry mouth and difficulty swallowing may occur.

Mydriasis is more typical, although miosis has also been reported.


Cardiovascular Effects

Hypotension may develop because of peripheral vasodilation.

In massive overdose, quinidine-like cardiac effects may produce:

Myocardial depression

and

Ventricular dysrhythmias.


Pulmonary Effects

Respiratory depression may occur, particularly when severe muscle weakness develops.


Gastrointestinal Effects

Vomiting may occur during overdose.


Hepatic Effects

Hepatitis has occasionally been reported.


Musculoskeletal Effects

Acute dystonic reactions may occur.

Very large overdoses may produce severe muscular weakness or paralysis.


Neurologic Effects

CNS depression is an important manifestation of overdose.

Patients may develop:

Somnolence → increasing CNS depression → coma

Other reported effects include:

Tremor

Hallucinations

and

Seizures.


Laboratory Evaluation

Asymptomatic patients may not require laboratory testing.

In symptomatic patients, investigations may be used to assess both toxicity and alternative causes of altered mental status.


Recommended Laboratory Tests

Useful studies may include:

Serum electrolytes

BUN

Creatinine

Glucose

and other tests directed by the clinical presentation.


Respiratory Assessment

Pulse oximetry may be used in symptomatic patients.

Arterial blood-gas analysis may be considered when there is significant respiratory depression or impaired oxygenation.


ECG

An ECG is useful in significant poisoning to look for:

QRS widening or other cardiac conduction abnormalities.


Screening for Coingestants

In an intentional or uncertain overdose, acetaminophen and salicylate concentrations may be obtained to identify occult coingestion.


Treatment

Supportive care is the mainstay of treatment.

The amount ingested, timing of exposure, and possible coingestants should be determined whenever possible.


When to Seek Toxicology Assistance

Poison-center or toxicology consultation is appropriate when:

Severe or persistent symptoms develop

or when:

A coingestant, drug interaction, or underlying disease complicates the clinical picture.


Referral to a Health-Care Facility

Medical evaluation is appropriate when:

Toxic effects occur

Intentional poisoning is suspected

or

The exposure history is unreliable or complicated.


Admission

Hospital admission or prolonged observation is usually unnecessary after a minor exposure.

Admission may be appropriate when the patient develops:

Significant CNS depression

or

Cardiovascular toxicity.


Decontamination – Out of Hospital

Vomiting should not be induced.


Decontamination – In Hospital

The historical approach recommended gastric lavage after a recent large ingestion or when serious toxicity was present.

A single dose of activated charcoal was also recommended after a substantial recent ingestion.

Airway protection is important because severe overdose may cause CNS depression or seizures.


Antidote

There is no specific antidote for trimethobenzamide poisoning.

Treatment remains supportive and symptom-directed.


Seizure Treatment

Airway protection should be maintained.

Benzodiazepines are used for initial seizure control.

If seizures persist or recur, another anticonvulsant such as phenobarbital may be added.


Dystonic Reactions

Acute dystonic reactions may be treated with:

Diphenhydramine 25–50 mg IV, IM, or orally

with repeated treatment as needed.

The original recommendation suggests continuing oral antihistamine treatment for approximately 3–5 days to reduce the risk of recurrent dystonia.


Hypotension

When hypotension is associated with clinically important bradycardia, atropine may be used.

Volume support may include:

0.9% saline 10–20 mL/kg IV

with further fluid treatment adjusted according to the patient’s response and risk of fluid overload.


Vasopressor Support

If hypotension persists despite fluid therapy, a vasopressor may be required.

The historical regimen included dopamine, starting at approximately:

2–5 μg/kg/min IV

and titrating according to the hemodynamic response.

Other vasopressors may be added when required for persistent hypotension.


Patient Monitoring

Symptomatic patients should have:

Cardiac monitoring

Supplemental oxygen when needed

and

IV access.

Neurologic and respiratory status should also be monitored.


Expected Course and Prognosis

Anticholinergic manifestations usually reach their maximum severity within several hours.

In more significant poisoning, symptoms may require:

24 hours or longer

to resolve completely.

Most patients recover with supportive care.


Discharge From the Emergency Department

An asymptomatic patient with normal vital signs may be considered for discharge after:

Appropriate decontamination when indicated

Approximately 4–6 hours of observation

and

Psychiatric assessment when appropriate.


Discharge From Hospital

Hospitalized patients may be discharged when:

Toxic effects have resolved

and

The patient has returned to a level of functioning sufficient for self-care.

Psychiatric assessment should be completed when indicated.


Important Pitfalls

Trimethobenzamide overdose may resemble other anticholinergic poisonings, so alternative toxicologic causes should be considered.


Large overdoses may produce more than uncomplicated anticholinergic toxicity.

CNS depression, seizures, hypotension, QRS widening, and ventricular dysrhythmias may occur.


Dystonic reactions may recur after initial improvement.

The original recommendation therefore advises continuing treatment with diphenhydramine or another appropriate agent for several days after the acute reaction.


High-Yield Toxicology Pearls

Trimethobenzamide is a nonphenothiazine antiemetic that primarily produces anticholinergic toxicity in overdose.


The typical overdose syndrome includes:

Dry mouth + mydriasis + tachycardia + CNS depression


Other manifestations may include:

Hyperthermia

Hallucinations

Tremor

Seizures

Hypotension

and

Dystonic reactions.


Massive overdose may produce:

Myocardial depression + QRS widening + ventricular dysrhythmias


Respiratory depression may occur when severe weakness or CNS depression develops.


There is no specific antidote.


Treatment is mainly:

Airway support + monitoring + seizure control + treatment of dystonia + hemodynamic support


For seizures:

Benzodiazepines first-line

with phenobarbital considered if seizures persist.


For acute dystonic reactions:

Diphenhydramine is the principal treatment described.


For hypotension:

IV crystalloid → vasopressor support if needed


Most patients recover with supportive care, although significant anticholinergic effects may persist for 24 hours or longer.


The main clinical warning is:

Trimethobenzamide overdose is usually mild, but a large ingestion can progress beyond simple anticholinergic symptoms to coma, seizures, hypotension, and cardiac conduction abnormalities.



Image description
0 Comments